Business
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
BOSTON, May 05, 2026--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Phase 1b/2 trial of PIKTOR in patients with HR+/HER2- advanced breast cancer. PIKTOR, an investigational, all-oral combination of serabelisib and sapanisertib, is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, and became Sensei's lead progra
About this update from Sensei Biotherapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/78827184fc8d8c4fdfb80a5a2d9de7ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yX.1wdcjWgJ6FaU4wCoUMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/78827184fc8d8c4fdfb80a5a2d9de7ac","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/OnSrEAhTnHT8nQZo5DUyYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/78827184fc8d8c4fdfb80a5a2d9de7ac","width":1024,"height":512}},"lazy":false},{"type":"text","content":"PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open","length":151,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 05, 2026--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Phase 1b/2 trial of PIKTOR in patients with HR+/HER2- advanced breast cancer. PIKTOR, an investigational, all-oral combination of serabelisib and sapanisertib, is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, and became Sensei's lead program after the company acquired Faeth Therapeutics in February 2026.","length":586,"tagName":"p"},{"type":"text","content":"Patients with HR+/HER2- advanced breast cancer whose tumors stop responding to current therapies have few effective options, particularly when their cancer is driven by the PI3K/AKT/mTOR signaling pathway, a network of growth and survival signals that is altered in approximately half of HR+/HER2- cases.¹ Study FTH-PIK-101, titled "Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients with HR+/HER2- Advanced or Metastatic Breast Cancer," is evaluating PIKTOR across HR+/HER2-advanced breast cancer patients, regardless of mutational status.","length":634,"tagName":"p"},{"type":"text","content":"The study is a multi-center, dose-escalation Phase 1b/2 trial evaluating sapanisertib and sera...